Companiesandmarkets.com

China Alzheimer's drugs market: CNY 20 billion industry in 2012

Press Release   •   Feb 25, 2013 16:55 GMT

The China Alzheimer's drugs market is estimated to have reached a value of around CNY 20.03 billion in 2012, growing by almost 24.5% over 2011. This is expected to increase at a rapid rate, and the China Alzheimer's drugs market is forecast to grow by between 20%-30% in the coming years. The development of China's economy, along with a general increase in the living standards of the Chinese populace has given increase exposure to the prevalence of elderly diseases such as Alzheimer's disease.

By the end of 2011, people aged 60 and above reached 185 million in China, accounting for 13.7% of the population, with an increase of 0.47 percentage point compared with that at the end of 2010. The elderly population in China will exceed 200 million by the end of 2013 and reach 221 million in 2015, accounting for 16% of the population, with a severe population aging trend. Globally, the GDP per capita of developed countries is generally between USD 5,000 and USD 10,000 when becoming aging nations. In over 70 aging-population countries worldwide, the GDP per capita of over 40% of them is more than USD 10,000. However, the GDP per capita of China was only over USD 5,000 in 2011, which indicated that China became an aging nation in advance.

AD is a primary nervous system degenerative disease caused by many factors. Clinically, it is characterized by progressive memory losses, decline in cognitive ability, abnormal behaviors and loss of self-care ability of daily living at last. AD is a common geriatric disease, and the incidence rate in China continuously rises in recent years.

In China, AD often occurs to people aged over 65, accounting for about 4% to 5% of population in this age group, with nearly 10% of people aged over 75 and around 20% of people aged above 85. It indicates that the morbidity rate of AD doubles with each 10-year-old increase in the age of the elderly.

According to conservative estimates, there are 8 million to 10 million senile dementia (mainly including AD, as well as vascular dementia(VD), mixed dementia and elderly dementia caused by systemic diseases) patients in China, of which less than half of them are able to receive effective treatment.

For more information on the China Alzheimer's drugs market, please click here: China Alzheimer's drugs market

For more information on the Healthcare and Medical market, please click here: Healthcare and Medical Reports

Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.